Old Web
English
Sign In
Acemap
>
Paper
>
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
2018
Sobhana Babu Boga
Yongqi Deng
Liang Zhu
Yang Nan
Alan B. Cooper
Gerald W. Shipps
Ronald J. Doll
Neng-Yang Shih
Hugh Zhu
Robert Sun
Tong Wang
Sunil Paliwal
Hon-Chung Tsui
Xiaolei Gao
Xin Yao
Jagdish Desai
James Wang
Abdul Basit Alhassan
Joseph Kelly
Mehul D. Patel
Kiran Muppalla
Subrahmanyam Gudipati
Li-Kang Zhang
Alexei V. Buevich
David Hesk
Donna Carr
Priya Dayananth
Hong Mei
Kathleen Cox
Bradley Sherborne
Alan Hruza
Li Xiao
Weihong Jin
Brian Long
Gongjie Liu
Stacey Taylor
Paul Kirschmeier
William T. Windsor
Robert Bishop
Ahmed A. Samatar
Keywords:
MAPK/ERK pathway
Cancer research
Bioavailability
Biology
Pharmacology
Chemistry
dual mechanism
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]